New antibiotic combo tested in kidney patients
NCT ID NCT07104162
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing a single dose of an experimental antibiotic combination (cefiderocol/xeruborbactam) given through a vein. The goal is to see how safe it is and how the body processes it in 40 adults with different levels of kidney function, including those on dialysis. The results will help determine the right dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cefiderocol/Xeruborbactam (a combination of two antibiotics given through a vein)
What this could lead to
If successful, this study will help doctors understand how to safely dose this antibiotic combination in patients with kidney problems, potentially leading to better treatment for serious bacterial infections.
What could go wrong
This is a very early (Phase 1) study with only 40 people, focused on safety and drug levels, not on curing infections. It may not lead to a new treatment, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
Contact
Contact
-
University of Miami Clinical Pharmacology
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact